Ascendis Pharma Gains Positive European Opinion for Achondroplasia Drug
Ascendis Pharma (ASND) received a positive regulatory recommendation in Europe for TransCon CNP, its once-weekly treatment for children aged two and older with achondroplasia whose growth plates remain open. Despite the favorable opinion from European regulators, the company's shares edged down 0.6% to close at $225.20, as investors had largely anticipated the outcome following the drug's earlier approval in the United States.
The drug, marketed as YUVIWEL in the U.S., received FDA approval in February 2026. While TransCon CNP represents a key component of the growth disorder portfolio for Ascendis Pharma, its current commercial contribution remains small. In its initial quarter of commercial sales, the drug generated between 7.6 million and 8 million euros, accounting for a minor portion of the company's 315 million euros in overall product sales, which are mostly led by YORVIPATH.
Looking ahead, European authorities are scheduled to make a final authorization decision in the fourth quarter of 2026. If approved, Ascendis Pharma anticipates its initial market launch in Germany during the first quarter of 2027. Chief Executive Officer Jan Mikkelsen noted that TransCon CNP remains a foundational therapy supporting the firm's long-term objectives. The company's stock has risen 6% year-to-date.
Key points
- Ascendis Pharma received a positive European regulatory opinion for its weekly achondroplasia drug, TransCon CNP.
- Ascendis Pharma shares fell 0.6% to $225.20 as investors had largely anticipated the European decision.
- TransCon CNP generated €7.6–8 million in its first quarter of commercial sales, out of €315 million in total product revenue.
- European Commission authorization is expected in Q4 2026, with a commercial launch planned in Germany for Q1 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What regulatory decision did Ascendis Pharma receive in Europe?
Ascendis Pharma received a positive regulatory opinion in Europe for TransCon CNP, a once-weekly treatment for children two years and older with achondroplasia whose growth plates are open.
When is TransCon CNP expected to launch in Europe?
A final authorization decision from the European Commission is expected in the fourth quarter of 2026, with a potential commercial launch in Germany planned for the first quarter of 2027.
How much revenue does TransCon CNP generate for Ascendis Pharma?
During its first quarter of commercial availability, TransCon CNP generated between 7.6 million and 8 million euros, accounting for a small portion of the company's 315 million euros in total product sales.